NRD
WST icon

Nebula Research & Development’s West Pharmaceutical WST Stock Holding History

Nebula Research & Development’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,445
Closed -$805K – 1196
2024
Q2 		$805K Buy
+2,445
New +$864K 0.13% 275

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's WST Position: Q3 2024 in Review

Nebula Research & Development sold out of West Pharmaceutical (WST) in Q3 2024, closing a stake of 2,445 shares — an estimated $805K sold.

Nebula Research & Development first reported a position in WST in Q2 2024 and held it in 1 quarter. The position peaked at $805K in Q2 2024. 729 funds tracked by Wall St. Rank hold WST as of Q3 2024.

  • Nebula Research & Development reported no remaining West Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 2,445 West Pharmaceutical shares in Q3 2024, an estimated $805K.
  • Nebula Research & Development first reported a position in West Pharmaceutical in Q2 2024 and held it in 1 quarter.
  • Nebula Research & Development's West Pharmaceutical position peaked at $805K in Q2 2024.
  • 729 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.